{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:52:00Z","timestamp":1785858720475,"version":"3.56.0"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1097\/01.fjc.0000180899.24865.b6","type":"journal-article","created":{"date-parts":[[2005,10,11]],"date-time":"2005-10-11T04:01:46Z","timestamp":1129003306000},"page":"609-614","source":"Crossref","is-referenced-by-count":21,"title":["Comparison of Two Doses and Dosing Regimens of Tolvaptan in Congestive Heart Failure"],"prefix":"10.1097","volume":"46","author":[{"given":"Paul J","family":"Hauptman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Udelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan E","family":"Shoaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Mallikaarjun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L","family":"Bramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare","family":"Orlandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210208","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3109\/08860229809045175","article-title":"Pathogenesis of sodium and water retention in cardiac failure.","volume":"20","author":"Schrier","year":"1998","journal-title":"Ren Fail"},{"issue":"Suppl 6","key":"R2-7-20210208","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1016\/S0002-8703(98)70254-6","article-title":"Current and novel pharmacologic approaches in advanced heart failure.","volume":"135","author":"OConnor","year":"1998","journal-title":"Am Heart J"},{"key":"R5-7-20210208","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1042\/cs0590443","article-title":"Hemodynamic and hormone responses to acute and chronic frusemide therapy in congestive heart failure.","volume":"59","author":"Ikram","year":"1980","journal-title":"Clin Sci"},{"key":"R6-7-20210208","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"key":"R7-7-20210208","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: a new target for the treatment of heart failure.","volume":"146","author":"Lee","year":"2003","journal-title":"Am Heart J"},{"key":"R10-7-20210208","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"R13-7-20210208","first-page":"36","article-title":"Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo-controlled randomized study comparing the effects of tolvaptan, furosemide and their combination (abstract).","volume":"9","author":"Udelson","year":"2003","journal-title":"J Card Fail"},{"key":"R14-7-20210208","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure. A randomized controlled trial.","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"R16-7-20210208","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cardfail.2005.03.009","article-title":"Rationale and design of the multicenter, randomized double-blind, placebo-controlled study to evaluate the efficacy of vasopressin antagonism in heart failure: outcome study with tolvaptan (EVEREST).","volume":"11","author":"Gheorghiade","year":"2005","journal-title":"J Card Fail"}],"container-title":["Journal of Cardiovascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-201703130-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:57:54Z","timestamp":1785855474000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005344-200511000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.fjc.0000180899.24865.b6","relation":{},"ISSN":["0160-2446"],"issn-type":[{"value":"0160-2446","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}